ストックスクリーナーアプリを入手
20.00
5.82%
1.10
前日終値:
$18.90
開ける：
$18.85
24時間の取引高:
183.56K
Relative Volume:
1.65
時価総額：
$168.78M
収益：
当期純損益:
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
1週間 パフォーマンス:
+0.65%
1か月 パフォーマンス:
-21.57%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$18.16
$20.94
52週間の値動き範囲:
$18.16
$44.28
Yarrow Bioscience, Inc. Common Stock Stock (YARW) Company Profile
Compare YARW vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
YARW
Yarrow Bioscience, Inc. Common Stock
|
20.00 | 168.78M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Yarrow Bioscience, Inc. Common Stock Stock (YARW) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-08-03 | 開始されました | BTIG Research | Buy |
| 2025-07-31 | ダウングレード | BTIG Research | Buy → Neutral |
| 2024-11-18 | 開始されました | BTIG Research | Buy |
| 2021-12-06 | 再開されました | H.C. Wainwright | Buy |
Yarrow Bioscience, Inc. Common Stock (YARW) 最新ニュース
A passive investor reports ownership of 1 million Yarrow Bioscience (YARW) shares. - Stock Titan
Raymond Debbane Reports 675,000 Shares in Yarrow Bioscience (NASDAQ: YARW) Representing 7.2% Passive Stake - Kalkine Media
New investor group tops 5% in Yarrow Bioscience (YARW) - Stock Titan
Yarrow Bioscience (NASDAQ: YARW) Grants Underwriters 30-Day Option for 865,384 Additional Shares - Kalkine Media
Yarrow Bioscience Raises About $161.8 Million in Public Stock Offering at $26 Per Share - TradingView
Yarrow Bioscience Files Prospectus for 25.78 Million Warrant-Linked Shares Offering (NASDAQ: YARW) - Kalkine Media
Yarrow Bioscience launches public offering of common stock - Investing.com India
Yarrow Bioscience Launches Public Offering of Common Stock - Yahoo Finance
Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering - Business Wire
Yarrow Bioscience prices $150M public offering at $26/share - Investing.com
Yarrow Bioscience Announces Proposed Underwritten Public Offering - Business Wire
YARW SEC FilingsYarrow Bioscience, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update - Business Wire
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update - BioSpace
OrbiMed Advisors Discloses Investment at Yarrow Bioscience with 9.97% Stake - TradingView
Yarrow Bioscience Alters Capital Structure With Warrant Exchange - TipRanks
Yarrow Bioscience, Inc. (YARW) Company Information - Simply Wall Street
Yarrow Bioscience (Nasdaq:YARW)Stock Analysis - Simply Wall Street
Yarrow Bioscience Completes VYNE Merger and Nasdaq Debut - TipRanks
Yarrow Bioscience Completes VYNE Merger and $200 Million Private Financing - citybiz
Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease - Yahoo Finance
VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience - Yahoo Finance
VYNE Therapeutics Announces 1-for-50 Reverse Stock Split, $17.3M Special Dividend, and Merger with Yarrow Bioscience – Minichart - Minichart
VYNE Sets $17.3M Cash Dividend Before Expected Yarrow Merger - Stock Titan
VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience - Yahoo Finance
VYNE Therapeutics and Yarrow Bioscience Announce Merger to Advance YB-101 for Graves' Disease and Thyroid Eye Disease - Quiver Quantitative
New biotech merger backs antibody targeting Graves’ and thyroid eye disease - Stock Titan
Yarrow Bioscience, Inc. Common Stock (YARW) 財務データ
Yarrow Bioscience, Inc. Common Stock (YARW) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.35%
大文字化:
|
ボリューム (24 時間):